Companies › ResMed Inc

ResMed Inc (RMD): Financial Statements and Key Figures

ResMed Inc (ticker RMD) is classified by the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus, and is listed on NYSE. It files its annual report with the U.S. Securities and Exchange Commission (SEC) on Form 10-K and reports in US dollars. Its fiscal 2026 ended on 30 June 2026; the annual report for that year was filed on 13 August 2026. For that year it reported revenue of US$ 5,653 million, net income of US$ 1,523 million and total assets of US$ 8,966 million at the year end. Fiscal years 2017 to 2026 are shown below.

The figures are as the company filed them, standardised by reporting tag; the filing is the authority. For education and analysis, not investment advice.

Key Figures

Money in US$ millions; earnings per share in US dollars. Free cash flow is the cash from operating activities less capital expenditures. Total debt is short-term plus long-term debt, or the total the company itself tags when that is larger. A margin is the profit line divided by revenue; return on equity is net income divided by the average of shareholders' equity at the start and the end of the year. A blank cell means the company does not report the line under a standard tag; it does not mean zero.

The last column is not a fiscal year. It is the last twelve months to 30 September 2026: the last fiscal year, plus the year to date in the latest quarterly report (Form 10-Q, filed 30 October 2026), less the same year-to-date period a year before; total assets, total debt and equity are those of the quarterly balance sheet. Quarterly reports are unaudited interim data. The column enters no growth rate and no chart.

Charts

Figure 1: Revenue and net income by fiscal year (US$ millions)

Figure 2: Cash from operating activities and free cash flow by fiscal year (US$ millions)

Compound Growth

The compound annual growth rate is the single yearly rate that, applied every year, takes the first value to the last one: the last value divided by the first, raised to the power of one over the number of years, less one. It uses only the two end values, so an unusual first or last year moves it a great deal.

• Revenue: 1,839 in fiscal 2016 to 5,653 in fiscal 2026 (US$ millions), 10 years: 11.9 % a year.
• Diluted earnings per share: 2.49 in fiscal 2016 to 10.43 in fiscal 2026 (US dollars per share), 10 years: 15.4 % a year.

Analyse This Company

Each link opens a calculator with ResMed Inc loaded from the same data.

• Company Financial Statements: The full income statement, balance sheet and cash flow statement of each fiscal year, with common-size and growth views.
• Capital Allocation History: Where the cash from operations went each year: capital expenditures, dividends, share repurchases, debt.
• Dividend Sustainability: How the dividends paid compare with earnings and with free cash flow, year by year.
• Earnings Quality Trend: How much of reported earnings arrived as cash, and how accruals moved over the years.
• Reverse DCF: The growth in free cash flow that a share price you type would assume.
• Financial Quality Scores: The Piotroski F-score and the DuPont breakdown of return on equity, worked step by step.
• Valuation Range: What a share price you type corresponds to as multiples of earnings, cash flow and book value, against the company's own history.

Several companies at once: Peer Comparison and Fundamental Screener.

Same Industry

The 6 other companies in the data with the industry code 3841 (Surgical & Medical Instruments & Apparatus), in alphabetical order; the index lists every company.

• 3M Co (MMM)
• Becton Dickinson & Co (BDX)
• Boston Scientific Corp (BSX)
• Dexcom Inc (DXCM)
• Stryker Corp (SYK)
• West Pharmaceutical Services Inc (WST)

Source

The annual report first filed for each fiscal year, with a link to its index page on EDGAR, the SEC's filing system. A later annual report repeats earlier years for comparison and sometimes restates them; where a value was taken from a later report, the last column gives the date of the latest one used.

• The figures are as filed with the SEC and standardised by reporting tag. The filing is the authority: check it before relying on a number.
• A blank cell means the company does not tag that line, or the tagged figure is withheld as incomplete. It does not mean zero.
• Currency: every figure is in the currency the company reported that year (US dollars here). Nothing is converted.
• Per-share figures are adjusted for stock splits detected from the company's own restated figures, except where a year is flagged; the as-filed values are in the filings.
• For a bank, broker, insurer or other financial company (SIC codes 6000 to 6799) net debt, EBITDA, the current ratio and debt to equity are not meaningful and the tools show them as n/m.
• A fiscal year is named after the calendar year in which it ends. The data is updated from time to time, not daily; this company's figures were loaded on 13 November 2026.

For education and analysis, not investment advice.